Board of Directors

Barry Coller, MD

The Rockefeller University

Vice President for Medical Affairs and Physician-in-Chief;
David Rockefeller Professor,
Allen and Frances Adler Laboratory of Blood and Vascular Biology;
The Rockefeller University

 

Dr Barry Coller earned a B.A., magna cum laude at Columbia College; an M.D. from NYU School of Medicine and completed his residency in internal medicine at Bellevue Hospital in New York. He became Assistant Professor of Medicine in the Division of Hematology at Stony Brook.

In addition to founding the Rockefeller University Center for Clinical and Translational Science he serves as PI for its Clinical and Translational Science Award from the National Center for Research Resources of the NIH. He currently serves as the founding President of the Society for Clinical and Translational Science, and as a member of the Advisory Council of the NHLBI and the national Principal Investigators’ CTSA Consortium Steering Committee.

Dr. Coller’s research interests have focused on hemostasis and thrombosis, in particular platelet physiology. He developed a monoclonal antibody that inhibits platelet function and a derivative of that antibody (abciximab; ReoProÔ; Centocor/Eli Lilly) was approved for human use by the FDA in 1994. It is now widely used to prevent ischemic complications of percutaneous coronary interventions such as angioplasty and stent insertion. He also developed an assay to assess platelet function, and automated derivatives of that assay to monitor therapy with abciximab, aspirin, and clopidogrel (Plavix™) have been approved for human use by the FDA (VerifyNow; Accumetrics). Dr. Coller is the recipient or a co-recipient of thirteen U.S. patents.

Board of directors »